pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) FDA catalysts & readout calendar

Updated ·next FDA decision on the calendar
no upcoming catalyst on file · 1 past FDA decision

FDA decision history (1)

Nov 18, 2025✓ ApprovedFDA decision
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates ARWR's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

ARWR run-up, measured

Computed from this stock's own daily closing prices, on the same T-120 basis as the run-up study: the baseline is the close 120 trading sessions before the eve of the decision. These are measurements of what already happened, not predictions.

ARWR's past FDA decisions (n=1)
DecisionOutcomeT-120 to eveT-120 to peak
2025-11-18APPROVAL+158.0%+172.4%
With only one decision on record, no median is shown: an average of 1 event would not be a meaningful statistic. The individual figures above are exact. For a statistical base see the run-up study, built on 1,839 decisions.

Common questions

When is the next FDA decision for Arrowhead Pharmaceuticals, Inc. (ARWR)?

Arrowhead Pharmaceuticals, Inc. has no dated FDA catalyst on our calendar right now. That means no scheduled decision or readout date has been published in a source we can point to, not that none exists. We would rather say that than estimate one.

Has Arrowhead Pharmaceuticals, Inc. (ARWR) had an FDA decision before?

Yes, 1 in our archive: 1 approval(s) and 0 Complete Response Letter(s). The most recent was on November 18, 2025 and was an approval. Each one has its own page with the source document and the share-price reaction we measured.

How do stocks like ARWR move into an FDA decision?

We have no measured history for ARWR itself. Across the whole study of 1,839 FDA decisions, the median stock rose 17.7% at its best point in the 120 trading days before the decision, but was only 2.0% higher the day before it. Most of the move happened before the answer arrived and was largely given back.

Where does this ARWR data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.